Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.64 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1970957 | 0.98 | TAAR1 (0.62) | TAAR1IDO1MAOBDAORAD52 | |
| SCHEMBL43792 | 0.87 | TAAR1 (0.56) | TAAR1IDO1MAOBHTR2ACACNA1H | |
| SCHEMBL806196 | 0.87 | TAAR1 (0.56) | TAAR1IDO1MAOBHTR2ACACNA1H | |
| SCHEMBL1587764 | 0.86 | IDO1 (0.50) | TAAR1IDO1MAOBDAORAD52 | |
| Hydrochloric Acid SCHEMBL23577777 | 0.86 | TAAR1 (0.55) | TAAR1IDO1MAOBHTR2A | |
| Hydrochloric Acid SCHEMBL3243140 | 0.86 | TAAR1 (0.55) | TAAR1IDO1MAOBHTR2A | |
| SCHEMBL3236622 | 0.86 | TAAR1 (0.55) | TAAR1IDO1MAOBHTR2ACACNA1H | |
| SCHEMBL16515444 | 0.86 | TAAR1 (0.55) | TAAR1IDO1MAOBHTR2A | |
| SCHEMBL7574477 | 0.85 | RAD52 (0.49) | TAAR1IDO1MAOBDAORAD52 | |
| Hydrochloric Acid SCHEMBL12520910 | 0.84 | TAAR1 (0.53) | TAAR1IDO1MAOBHTR2ACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117043140-A | Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-11-10 | — | — | CN | claimed |
| EP-1338592-B1 | Novel 2-phenylpiperazine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2009-01-21 | — | — | EP | claimed |
| JP-2006521344-A | — | — | 2006-09-21 | — | — | JP | claimed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | claimed |
| WO-2006032987-A1 | INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-6951861-B1 | Chemical compounds | SMITHKLINE BEECHAN CORPORATION (US) | 2005-10-04 | — | — | US | claimed |
| EP-1530562-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | Central Glass Company, Limited (JP) | 2005-05-18 | — | — | EP | claimed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | claimed |
| WO-2004022521-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-03-18 | — | — | WO | claimed |
| US-6124296-A | NEUROKININ (TACHYKININ) ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 2000-09-26 | — | — | US | claimed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117043140-A | Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidal active substances | 拜耳公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116768737-A | Preparation method of interface passivation material and perovskite passivation layer | 武汉理工大学 | 2023-09-19 | — | — | CN | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| US-5585385-A | USEFUL IN TREATING DISORDERS OF MICTURITION; ADMINISTERING TO INHIBIT PLASMA EXTRAVASATION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-17 | — | — | US | disclosed |
| US-5482967-A | LOWERING CHOLESTEROL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| EP-0652218-A1 | Heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1995-05-10 | — | — | EP | disclosed |
| EP-0585913-A2 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122224-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | TAAR1 1109/4885IDO1 1293/4885MAOB 957/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | TAAR1 2042/4885IDO1 137/4885MAOB 149/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | TAAR1 1109/4885IDO1 1293/4885MAOB 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.